Latest Articles
- ArticleLongitudinally Extensive Myelitis Associated With Immune Checkpoint InhibitorsAlberto Picca, Giulia Berzero, Kevin Bihan, et al.February 26, 2021
- ArticleDiscontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 AntibodiesSu-Hyun Kim, Hyunmin Jang, Na Young Park, et al.February 23, 2021
- ArticleEpigallocatechin Gallate in Progressive MSA Randomized, Placebo-Controlled TrialRebekka Rust, Claudia Chien, Michael Scheel, et al.February 23, 2021
- ArticleClinical and Radiologic Disease Activity in Pregnancy and Postpartum in MSAnnika Anderson, Kristen M. Krysko, Alice Rutatangwa, et al.February 19, 2021
- Clinical/Scientific NotesDisseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With FingolimodAleksandra A. Abrahamowicz, Eric J. Chow, Daniel D. Child, et al.February 18, 2021
- ArticleInterferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MSYuyi You, Michael H. Barnett, Con Yiannikas, et al.February 17, 2021
- ArticleMass Cytometry of CSF Identifies an MS-Associated B-cell PopulationDavid Johansson, Céline Rauld, Julien Roux, et al.February 15, 2021
- ArticleLong-term Functional Outcomes and Relapse of Anti-NMDA Receptor EncephalitisA Cohort Study in Western ChinaXue Gong, Chu Chen, Xu Liu, et al.February 15, 2021
- ArticleImprovement of Comorbid Psoriasis in Patients With MS Treated With NatalizumabRegina Berkovich, Aida Yakupova, Jonathan Eskenazi, et al.February 15, 2021
- ArticleDefining Benign/Burnt-Out MS and Discontinuing Disease-Modifying TherapiesDerek McFaul, Nektar N. Hakopian, Jessica B. Smith, et al.February 08, 2021
Pages
Advertisement